医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Growth of DCAT Week Spurs Expansion of Annual Event’s NYC Meeting Space

2016年07月27日 PM08:30
このエントリーをはてなブックマークに追加


 

ROBBINSVILLE, N.J.

Due to the significant increase in attendance and opportunities for updated business meeting space, the Drug, Chemical & Associated Technologies Association (DCAT) announced it will be expanding its flagship event, DCAT Week (March 20-23, 2017), by introducing four additional venues in Midtown Manhattan. DCAT Week is the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries.

Attracting thousands of high-level decision makers annually, DCAT Week has increased its business meeting space block for member companies by 97 percent, and attendance at education programs is up 129 percent. Overall, the organization has experienced a 37 percent increase in total member companies since 2010.

“We are tremendously excited about the growth of our event and the expansion of the DCAT Week neighborhood,” said DCAT Executive Director Margaret Timony. “The different meeting spaces at our eight Official DCAT Week Hotels present us with some fantastic opportunities for new networking events, member lounge space and branding opportunities. But most importantly, we can offer our members updated rooms, amenities and technologies for their important business meetings.”

The 91st DCAT Annual Dinner will be relocated to the ballroom of the New York Hilton Midtown to accommodate more guests in a venue with greater capacity. “It will be fantastic to gather the DCAT community into a single room to celebrate the end of another successful DCAT Week,” said DCAT First Vice President and Annual Dinner Chair Joe Sutton (Eli Lilly and Company). Transportation for guests will also be provided to and from the dinner from all Official DCAT Week Hotels.

To learn more about the exciting new developments for DCAT Week ’17 visit www.dcat.org/DCATWeek.htm and join the conversation at #DCATWEEK.

About DCAT

DCAT is a 501(c)6, not-for-profit, member-supported, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. www.dcat.org

View source version on businesswire.com: http://www.businesswire.com/news/home/20160727005162/en/

CONTACT

Drug, Chemical & Associated Technologies Association
Erin
Sanders, 609-208-1888
Director of Communications
esanders@dcat.org
or
Brandwidth
Solutions LLC
Debra Harrsch, 215-997-8575
dharrsch@brandwidthsolutions.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果